Session Chair Profile

Ph.D., Partner, Morrison & Foerster LLP
Biography

Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing effective portfolio counseling and management. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including personalized medicine, cancer and cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular disease, metabolic disorders, and neurodegenerative diseases such as Alzheimer’s Diseases. She also works with small and large molecule therapies, drug delivery and formulation technologies, cell-based therapies, tumor microenvironment, microfluidics and genomic screening technologies. Her practice also includes due diligence evaluation and counseling in the context of venture investment assessments, as well as in connection with public and private financings, spin-offs, partnerships, and mergers and acquisitions. Dr. Polizzi is recognized as a leader in intellectual property law, including as a top intellectual property attorney in California for almost 10 years running, and is an inductee of the Legal Media Group Life Sciences Hall of Fame.

Session Abstract – PMWC 2019 Silicon Valley

Session Synopsis: This session will review key developments in IP law and their impact on patent strategy with a focus on precision medicine and immuno-oncology. The session will provide background and updates on patent eligibility (section 101), tradeoffs between eligibility and the ability to effectively sue infringers. In addition, discuss legal developments that impact patent strategy for antibody or TCR-based products.

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.